Language
Contact
Search
Menu

TAS7500SP

Contact Contact
Terahertz Spectroscopic Analysis System TAS7500 Series

Terahertz Spectroscopic System for spectroscopic analysis of chemical substances, pharmaceutical products, etc.

  • Four interchangeable measurement modules enable diverse analysis functions
  • Supports measurement of specimens in liquid, solid, and powder forms
  • Easy module switching requires no adjustments
  • Attached dry air unit eliminates moisture interference
Supported measurement modules (Option) Transmission / reflection / ATR / transmittance polarization analysis
Target materials Pharmaceutical tablets / liquids / powders, other reagents, chemical substances
Analysis / display functions Spectral display (transmittance, reflectance, ATR, phase shift, absorbance, absorption coefficient, complex refractive index, complex permittivity), time response display (electric field strength), quantitative analysis (optional)
Frequency range 0.1-4THz (at 23°C ±5°C)
Scan rate <8ms / scan

Application Pharmaceutical: Crystalline/Amorphous Analysis

Analysis of crystal polymorphism

THz spectroscopy has many applications in the development of various healthcare products. Absorption in the THz frequency range is sensitive to crystal lattice vibrations. These absorptions provide a characteristic spectrum of the crystal forms, thus enabling a new method for analyzing polymorphs.

Example of transmission measurement of crystal polymorph with THz waves (*1), (*2)

Compound A(*3) has a crystal polymorph that is difficult to distinguish by a PXRD analysis. Using THz spectroscopy, the crystal forms of a medicinal product can be determined and monitored in seconds.

  1. Y. Ikeda, E. Kato, K. Terada et al., Chem. Pharm. Bull., 58 (2010) 76.
  2. Y. Ikeda, E. Kato, K. Terada et al., Proceedings of the 25th Annual Meeting of the Academy of Pharmaceutical Science and Technology, Japan (2010) 201
  3. Provided by Takeda Pharmaceutical Company Limited.

Crystallinity

Using a TAS7500 system to observe the crystallization process of non-crystalline indomethacin (100%) over a 10-day period, the phase transition into the γ-crystalline form is confirmed.

User Support

ExcelPDF